PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23629159-0	2014	Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent.	efavirenz	0-9	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	57-64	
16267764-1	2005	BACKGROUND: Efavirenz and nelfinavir are metabolized by cytochrome P-450 (CYP) 2B6 and CYP2C19, respectively, with some involvement by CYP3A.	efavirenz	12-21	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	87-94	
16267764-9	2005	Plasma exposure to efavirenz and nelfinavir in each population was significantly associated with the polymorphisms CYP2B6 516G-->T and CYP2C19 681G-->A, respectively.	efavirenz	19-28	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	138-145	
23629159-2	2014	We hypothesized that CYP2C19 and CYP2B6 genetic polymorphisms influence the extent of induction of omeprazole metabolism by efavirenz.	efavirenz	124-133	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	21-28	
22318618-2	2012	We evaluated the effects of multiple doses of efavirenz on omeprazole 5-hydroxylation (CYP2C19) and sulfoxidation (CYP3A).	efavirenz	46-55	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	87-94	
23385314-3	2013	Efavirenz was a moderate inhibitor of CYP2C9 (K(i) = 19.46 microM) and CYP2C19 (K(i) = 21.31 microM); and a weak inhibitor of CYP3A (K(i) = 40.33 microM).	efavirenz	0-9	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	71-78